Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc. reports news on its global medtech business, which supplies hospitals, physician offices and other care settings with connected solutions, medical devices and advanced injectable technologies. Company updates commonly cover results from continuing operations following the Kidney Care divestiture, portfolio activity in infusion therapies and platforms, surgical tables, smart stretchers, patient-support systems, monitoring tools, and hemostatic and sealing agents.
Baxter announcements also address product introductions such as the IV Verify Line Labeling System, conference showcases for Global Surgical Solutions, Advanced Surgery and Patient Support Systems, annual-meeting matters, executive finance leadership, and foundation partnerships tied to healthcare settings.
Baxter (NYSE:BAX) has appointed John Rogers as executive vice president and chief financial officer, effective Oct. 1, 2026, reporting to president and CEO Andrew Hider. The company highlighted his experience leading complex transformation initiatives and strengthening financial discipline across global organizations.
Rogers previously served as CFO of Smith+Nephew and WPP and held senior roles at J Sainsbury, including CEO of Sainsbury’s Argos and CFO. He also has public-company board experience with Grab Holdings and Travis Perkins. Baxter reiterated its full-year 2026 financial outlook previously issued on July 30, 2026.
Baxter (NYSE:BAX) has announced final pricing and allocation for its upsized cash tender offers for certain outstanding senior notes. The aggregate purchase price cap (excluding accrued interest) was increased from $500 million to $600 million, using a “waterfall” acceptance by priority level.
According to Baxter, at the Aug. 18, 2026 price determination time, the company expects to purchase the full tendered amounts of its 3.132% notes due 2051, 3.500% notes due 2046, 4.500% notes due 2043, and a prorated portion (proration factor about 31.37%) of its 2.539% notes due 2032. Aggregate principal amounts accepted are approximately $422 million, $132 million, $73 million and $237 million, respectively, for a total purchase price of $600 million.
Holders whose notes are accepted and were tendered by the Aug. 17, 2026 early tender time will receive “Total Consideration” per $1,000 principal amount that includes a $30 early tender premium, plus accrued interest, payable on the Aug. 20, 2026 early settlement date. Because tenders before the early deadline exceeded the cap, no notes tendered after that time will be accepted and there will be no final settlement date.
Baxter (NYSE:BAX) reported early tender results for its previously announced cash tender offers for four series of senior notes and increased the aggregate purchase price cap (excluding accrued interest) from $500 million to $600 million.
As of the Early Tender Time (5:00 p.m., New York City time, Aug. 17, 2026), holders had validly tendered and not validly withdrawn $421.99 million of 3.132% notes due 2051, $132.199 million of 3.500% notes due 2046, $72.744 million of 4.500% notes due 2043, and $756.712 million of 2.539% notes due 2032.
Baxter will apply a “waterfall” based on acceptance priority levels, subject to the $600 million Offer Cap. Pricing will be set at 10:00 a.m., Aug. 18, 2026, using fixed spreads over Reference U.S. Treasury yields. Early-tendering holders accepted for purchase receive Total Consideration including a $30 per $1,000 Early Tender Premium, plus accrued interest, with settlement expected on Aug. 20, 2026.
Baxter (NYSE:BAX) has launched cash tender offers for four series of senior notes using a “waterfall” acceptance method, subject to a maximum aggregate purchase price (excluding interest) of $500 million. Targeted issues include 3.132% notes due 2051, 3.500% notes due 2046, 4.500% notes due 2043 and 2.539% notes due 2032.
Holders who tender by the Early Tender Time of 5:00 p.m., August 17, 2026 and are accepted will receive the Total Consideration, which embeds an early tender premium of $30 per $1,000 principal. The Offers expire at 5:00 p.m., September 1, 2026, with expected settlement on August 20 for early tenders and September 3, 2026 for later tenders. Baxter may increase, decrease or waive the $500 million Offer Cap, subject to the Offer to Purchase and applicable law.
Baxter (NYSE:BAX) reported second-quarter 2026 net sales of $2.96 billion, up 5% on both reported and organic bases, with growth across all segments and regions. U.S. sales rose 4% to about $1.6 billion, while international sales increased 7% reported and 5% organically to about $1.4 billion.
GAAP diluted EPS from continuing operations was $0.26, and adjusted diluted EPS was $0.56, down 5% year over year, including a $0.11 benefit from an IEEPA tariff refund. Operating income was $217 million, up 14%, and free cash flow reached $181 million in the quarter. Medical Products & Therapies sales grew 7% reported (5% organic) to roughly $2.1 billion, and Healthcare Systems & Technologies sales increased 4% to about $801 million. Baxter raised its full-year 2026 outlook to reported sales growth of 3%–4%, organic growth of 2%–3%, and adjusted EPS of $1.95–$2.15.
Baxter (NYSE:BAX) will host a conference call for investors to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time.
Investors can access the live webcast via Baxter’s website and are asked to pre-register online to receive detailed call information.
Baxter (NYSE:BAX) released its 2025 Sustainability Report, outlining a refreshed strategy, new governance and updated long-term targets. The report describes progress in sustainable healthcare, operational efficiency, environmental stewardship and employee well-being, plus more than $32 million in community contributions through the company and the Baxter Foundation.
New goals include Net-Zero Scope 1 and 2 GHG emissions by 2050, 100% renewable electricity by 2040, expanded science-based supplier targets, and enhanced community investment and employee volunteer objectives, aligned with Baxter’s Growth and Performance System.
MediThinQ and Synovis Micro Companies Alliance, a Baxter (NYSE:BAX) subsidiary, signed an exclusive multi-year global distribution agreement for the SHIYA 3D surgical visualization platform. The deal leverages Synovis MCA’s microsurgery network to support phased worldwide rollout and adoption of digital, data-enabled 3D exoscope-based microsurgery.
4D Path (BAX) announced the first close of a strategic financing to accelerate development of treatment‑predictive biomarkers for solid tumors and partnerships with biopharma. The company appointed Katherine Vega Stultz as Board Chair and added Robert J. Hombach to the board to strengthen clinical, commercial and financial leadership.
The release highlights pan‑cancer potential and prior clinical relevance across breast, ovarian, colorectal and skin cancers, and frames the board changes plus financing as catalysts for accelerated growth and partnership activity.
Baxter (NYSE: BAX) reported continuing-operations sales of $2.7B for Q1 2026, up 3% reported and down 1% organic. U.S. sales were $1.44B (down 4%), international sales $1.27B (up 12% reported). GAAP loss per share was ($0.03); adjusted EPS was $0.36 (down 35%). Company reiterated full-year 2026 outlook: reported sales flat to 1%, organic approximately flat, adjusted EPS $1.85–$2.05.